MedTrace Logo

Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas

NCT03071874 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2022-10-18

No results posted yet for this study

Summary

This research study is studying a chemotherapy as a possible treatment for Meningiomas (recurrent).

The study intervention involved in this study is:

--AZD2014 (vistusertib)

Conditions

  • Meningioma

Interventions

DRUG

AZD2014

AZD2014 is a dual mTORC1/mTORC2 inhibitor

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • AstraZeneca

    collaborator INDUSTRY

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Scott R. Plotkin, MD, PhD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-17
Primary Completion
2022-06-30
Completion
2024-07-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03071874 on ClinicalTrials.gov